Septerna (SEPN) Stock Price, News & Analysis

Company Overview

Septerna, Inc. is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule medicines that target G protein-coupled receptors (GPCRs). GPCRs are a large class of cell-surface proteins involved in a wide range of biological processes and represent an important source of potential drug targets.

The company’s research is powered by its Native State platform, which is designed to study GPCRs in their natural biological configuration and support the discovery of selective small-molecule compounds. Septerna is applying this approach to develop medicines for diseases with significant unmet medical needs, including potential treatments in immunology, inflammation and other therapeutic areas.

Septerna’s pipeline consists of internally discovered drug candidates at various stages of preclinical and clinical development. As a biotechnology company, its operations are primarily centered on research, drug discovery and clinical development rather than the sale of marketed products. Septerna is headquartered in the United States and trades on the Nasdaq under the symbol SEPN.

Key Stats

• Today's Range: $42.22 to $44.58
• 50-Day Range: $35.67 to $45.23
• 52-Week Range: $17.55 to $51.10
• Volume: 307,510 shs
• Average Volume: 378,831 shs
• Market Capitalization: $2.04 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $52.44
• Consensus Rating: Moderate Buy

Septerna Stock Analysis - MarketRank™

Septerna scored higher than 45% of companies evaluated by MarketBeat, and ranked 572nd out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Septerna has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 1 strong buy rating, 8 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Septerna has a consensus price target of $52.44, representing about 20.0% upside from its current price of $43.70.

Amount of Analyst Coverage

Septerna has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Septerna are expected to decrease in the coming year, from ($1.41) to ($2.21) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Septerna is -80.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Septerna is -80.93, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Septerna has a P/B Ratio of 5.12. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.01% of the float of Septerna has been sold short.

Short Interest Ratio / Days to Cover

Septerna has a short interest ratio ("days to cover") of 7.63.

Change versus previous month

Short interest in Septerna has recently increased by 13.78%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Septerna does not currently pay a dividend.

Dividend Growth

Septerna does not have a long track record of dividend growth.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.74

News Sentiment

Septerna has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Septerna this week, compared to 3 articles on an average week.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Septerna insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,490,650.00 in company stock.

Percentage Held by Insiders

5.80% of the stock of Septerna is held by insiders.

Percentage Held by Institutions

Septerna has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 11/03/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SEPN
• Previous Symbol: NASDAQ:SEPN
• CIK: 1984086
• Web: septerna.com
• Phone: (650) 338-3533
• Fax: N/A
• Employees: 130
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Septerna: $52.44
• High Price Target: $62.00
• Low Price Target: $43.00
• Potential Upside/Downside: +20.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.82
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.54)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$48.88 million
• Net Margins: -24.51%
• Pretax Margin: -23.17%
• Return on Equity: -9.57%
• Return on Assets: -6.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.99
• Quick Ratio: 4.99

Sales & Book Value

• Annual Sales: $45.95 million
• Price / Sales: 44.39
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.53 per share
• Price / Book: 5.12

Miscellaneous

• Outstanding Shares: 46,680,000
• Free Float: 43,970,000
• Market Cap: $2.04 billion
• Optionable: Optionable
• Beta: 2.20